Versa Erasable Slate
by LS&S
Last verified June 19, 2026 · classified April 26, 2026
What it is
Summary
AI-generated from vendor-published content · April 26, 2026
The Versa Erasable Slate is a reusable braille writing tool that lets you press braille dots into a plastic surface across a 4-row, 20-cell-per-row grid, then flip the slate over to read what you've written — no paper or stylus required. It's well-suited for blind or low-vision users who want a quick, quiet way to jot down notes on the go, or for students learning to write braille who need a low-stakes surface to practice on without consuming paper. This is a self-contained, standalone device — nothing else needed to use it. The slate holds only 80 cells total (roughly a few short sentences), so it's designed for brief notes rather than extended writing sessions.
Quick Facts Catalog facts · auto-generated
- AT Act lending
- Out of pocket
- School district
- Vocational rehab
What Setup Looks Like
- Out of the box
- Press braille dots into the cells using your fingertips — no stylus or paper needed.
- Flip the slate over to read the embossed braille message.
- Press the erase buttons (4 sets, each clearing 5 cells) to reset and reuse.
Getting it
Try Before You Buy
Devices like this are often available to borrow through your state's AT Act program — typically free or low-cost — so you can try it before buying or pursuing funding.
Where to Get It
Some links may be affiliate links — WhatCanHelp may earn a small commission from purchases at no extra cost to you. More on affiliates →
As an Amazon Associate we earn from qualifying purchases.
How to Fund This
Equipment like this is often pursued through official state programs. These are common starting points — each program decides its own eligibility and what it covers, so the first step is always a phone call.
Compare & explore
Sources & fine print
Vendor facts (name, price, platforms, vendor link) sourced from LS&S — view on vendor site; last verified June 19, 2026.
Classification & description AI-generated from vendor-published content on April 26, 2026 · confidence: high. Vendor specs may lag; verify before relying on details in a clinical or funding artifact.